Regal Partners Ltd Acquires Shares of 10,000 GeneDx Holdings Corp. (NASDAQ:WGS)

Regal Partners Ltd bought a new stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,000 shares of the company's stock, valued at approximately $769,000.

Several other hedge funds have also bought and sold shares of WGS. Emerald Mutual Fund Advisers Trust bought a new stake in shares of GeneDx during the 4th quarter valued at $4,430,000. Northern Trust Corp raised its holdings in GeneDx by 19.7% during the fourth quarter. Northern Trust Corp now owns 179,651 shares of the company's stock valued at $13,808,000 after acquiring an additional 29,608 shares during the period. Tudor Investment Corp ET AL lifted its position in shares of GeneDx by 67.7% in the fourth quarter. Tudor Investment Corp ET AL now owns 101,810 shares of the company's stock valued at $7,825,000 after acquiring an additional 41,084 shares in the last quarter. Quarry LP purchased a new position in shares of GeneDx in the fourth quarter valued at about $78,000. Finally, Tri Locum Partners LP bought a new position in shares of GeneDx in the fourth quarter worth about $9,805,000. Institutional investors own 61.72% of the company's stock.

GeneDx Price Performance

Shares of GeneDx stock traded down $1.36 during trading hours on Monday, reaching $65.87. The company's stock had a trading volume of 712,822 shares, compared to its average volume of 1,133,929. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. GeneDx Holdings Corp. has a one year low of $18.80 and a one year high of $117.75. The firm has a 50 day moving average price of $94.30 and a 200-day moving average price of $82.91. The stock has a market cap of $1.85 billion, a P/E ratio of -33.61 and a beta of 1.93.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.17. The business had revenue of $87.12 million for the quarter, compared to the consensus estimate of $79.90 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. On average, analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on WGS shares. TD Securities dropped their price target on GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research note on Thursday. TD Cowen raised their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, January 7th. The Goldman Sachs Group boosted their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. Finally, Wells Fargo & Company cut their price objective on GeneDx from $105.00 to $78.00 and set an "equal weight" rating for the company in a research report on Thursday. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $78.14.

Insider Buying and Selling

In related news, CFO Kevin Feeley sold 402 shares of GeneDx stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $90.05, for a total value of $36,200.10. Following the completion of the sale, the chief financial officer now directly owns 5,044 shares in the company, valued at $454,212.20. The trade was a 7.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Katherine Stueland sold 46,594 shares of the firm's stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $89.62, for a total transaction of $4,175,754.28. Following the transaction, the chief executive officer now directly owns 1,720 shares in the company, valued at $154,146.40. This trade represents a 96.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 139,390 shares of company stock valued at $13,043,288 in the last ninety days. 27.30% of the stock is owned by company insiders.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.